DIFF Subgroup
A61K 40/40 characterised by antigens that are targeted or presented by cells of the immune system
Introduced: January 2025
Full Title
Full titles differ between systems:
IPC:
Cellular immunotherapy > characterised by antigens that are targeted or presented by cells of the immune system
CPC:
Cellular immunotherapy (medicinal preparations containing antigens or antibodies A61K39/00) > characterised by antigens that are targeted or presented by cells of the immune system
Of 8 combined children, 6 exist in both systems.
2 codes are CPC-only extensions.
IPC defines codes here since 2025.
Child Classifications
Navigate with arrow keys, Enter to open
Top Applicants
Top Applicants (IPC)
Class A61,2013–2023, worldwide · Source: EPO PATSTAT
- PHILIPS ELECTRONICS NL 18,523
- NOVARTIS CH 14,253
- COVIDIEN US 13,953
- ROCHE CH 12,005
- CHINESE ACADEMY OF SCIENCES 11,955
- UNIVERSITY OF CALIFORNIA US 11,692
- HARVARD UNIVERSITY US 11,596
- L'OREAL FR 11,593
- P&G (PROCTER & GAMBLE COMPANY) US 11,297
- OLYMPUS CORPORATION JP 9,594
Top Applicants (CPC)
Class A61,2013–2023, worldwide · Source: EPO PATSTAT
- PHILIPS ELECTRONICS NL 20,621
- NOVARTIS CH 15,792
- ROCHE CH 14,303
- COVIDIEN US 13,862
- HARVARD UNIVERSITY US 13,454
- UNIVERSITY OF CALIFORNIA US 12,798
- P&G (PROCTER & GAMBLE COMPANY) US 12,140
- L'OREAL FR 11,800
- OLYMPUS CORPORATION JP 9,894
- BOSTON SCIENTIFIC SCIMED US 9,513